Merck finally rolls out sleep aid Belsomra after FDA roadblocks

Merck's ($MRK) long-awaited insomnia drug Belsomra (suvorexant) has now hit pharmacy shelves in the U.S. The drug is a first-in-class sleep aid finally approved last year after an initial rejection by the FDA. Early analyst estimates had put 2017 sales at more than $500 million, but after the agency chose to approve a lower dose than hoped for, those forecasts fell to about $300 million. Release

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.